Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction
Open Access
- 1 January 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Heart Failure
- Vol. 4 (1), 27-35
- https://doi.org/10.1161/circheartfailure.109.932996
Abstract
Background— The determinants of prognosis in patients with heart failure and preserved ejection fraction (HF-PEF) are poorly documented. Methods and Results— We evaluated data from 4128 patients in the I-PRESERVE trial (Irbesartan in Heart Failure with Preserved Ejection Fraction Study). Multivariable Cox regression models were developed using 58 baseline demographic, clinical, and biological variables to model the primary outcome of all-cause mortality or cardiovascular hospitalization (1505 events), all-cause mortality (881 events), and HF death or hospitalization (716 events). Log N-terminal pro–B-type natriuretic peptide, age, diabetes mellitus, and previous hospitalization for HF were the most powerful factors associated with the primary outcome and with the HF composite. For all-cause mortality, log N-terminal pro–B-type natriuretic peptide, age, diabetes mellitus, and left ventricular EF were the strongest independent factors. Other independent factors associated with poor outcome included quality of life, a history of chronic obstructive lung disease, log neutrophil count, heart rate, and estimated glomerular filtration rate. The models accurately stratified the actual 3-year rate of outcomes from 8.1% to 59.9% (primary outcome) 2.7% to 36.5% (all-cause mortality), and 2.1% to 38.9% (HF composite) for the lowest to highest septiles of predicted risks. Conclusions— In a large sample of elderly patients with HF and preserved EF enrolled in I-Preserve, simple clinical, demographic, and biological variables were associated with outcome and identified subgroups at very high and very low risk of events. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00095238.Keywords
This publication has 38 references indexed in Scilit:
- Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trialThe Lancet, 2010
- Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction TrialJournal of Cardiac Failure, 2010
- Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiologyEuropean Journal of Heart Failure, 2009
- The Seattle Heart Failure ModelCirculation, 2006
- Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart FailureCirculation, 2006
- Neurohumoral Pathways in Heart Failure With Preserved Systolic FunctionProgress in Cardiovascular Diseases, 2005
- Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: A retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention TrialAmerican Heart Journal, 2004
- Validity of the minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placeboThe American Journal of Cardiology, 1993
- Predictors of total mortality and sudden death in mild to moderate heart failureJournal of the American College of Cardiology, 1989
- Regression modelling strategies for improved prognostic predictionStatistics in Medicine, 1984